OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Risk of serious infections in multiple sclerosis patients by disease course and disability status: Results from a Swedish register-based study
Judith S. Brand, Kelsi A Smith, Fredrik Piehl, et al.
Brain Behavior & Immunity - Health (2022) Vol. 22, pp. 100470-100470
Open Access | Times Cited: 21
Judith S. Brand, Kelsi A Smith, Fredrik Piehl, et al.
Brain Behavior & Immunity - Health (2022) Vol. 22, pp. 100470-100470
Open Access | Times Cited: 21
Showing 21 citing articles:
Association Between Anti-CD20 Therapies and COVID-19 Severity Among Patients With Relapsing-Remitting and Progressive Multiple Sclerosis
Édouard Januel, David Hajage, Pierre Labauge, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2319766-e2319766
Open Access | Times Cited: 23
Édouard Januel, David Hajage, Pierre Labauge, et al.
JAMA Network Open (2023) Vol. 6, Iss. 6, pp. e2319766-e2319766
Open Access | Times Cited: 23
Immunosenescence and multiple sclerosis: inflammaging for prognosis and therapeutic consideration
Smathorn Thakolwiboon, Elizabeth Mills, Jennifer Yang, et al.
Frontiers in Aging (2023) Vol. 4
Open Access | Times Cited: 21
Smathorn Thakolwiboon, Elizabeth Mills, Jennifer Yang, et al.
Frontiers in Aging (2023) Vol. 4
Open Access | Times Cited: 21
Tetanus and Diphtheria Toxoid-Containing Vaccine in Multiple Sclerosis Patients: A Real-World Prospective, Open-Label, Multi-Centre Study
Alexander Winkelmann, Emil C. Reisinger, Katharina Boden, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 451-451
Open Access
Alexander Winkelmann, Emil C. Reisinger, Katharina Boden, et al.
Vaccines (2025) Vol. 13, Iss. 5, pp. 451-451
Open Access
Hypogammaglobulinemia and Infection Risk in an Ocrelizumab-treated Multiple Sclerosis Cohort
S Nobile, Philippe Beauchemin
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024) Vol. 51, Iss. 6, pp. 811-818
Open Access | Times Cited: 3
S Nobile, Philippe Beauchemin
Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques (2024) Vol. 51, Iss. 6, pp. 811-818
Open Access | Times Cited: 3
De-escalation and Discontinuation of Disease-Modifying Therapies in Multiple Sclerosis
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 3
Robert Gross, John R. Corboy
Current Neurology and Neuroscience Reports (2024) Vol. 24, Iss. 9, pp. 341-353
Closed Access | Times Cited: 3
Infektionen und Multiple Sklerose
Felicita Heidler, Tobias Bopp, Matthias Schwab, et al.
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 2
Felicita Heidler, Tobias Bopp, Matthias Schwab, et al.
Fortschritte der Neurologie · Psychiatrie (2024)
Closed Access | Times Cited: 2
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Susanna Hallberg, Björn Evertsson, Ellen Lillvall, et al.
European Journal of Neurology (2024) Vol. 31, Iss. 8
Open Access | Times Cited: 2
Hypogammaglobulinemia and severe infections in Multiple Sclerosis patients on anti-CD20 agents: a multicentre study
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
Krzysztof Smolik, Federico Camilli, Ivan Panzera, et al.
Multiple Sclerosis and Related Disorders (2024) Vol. 93, pp. 106191-106191
Open Access | Times Cited: 2
Serious infections in patients with relapsing and progressive forms of multiple sclerosis: A German claims data study
Rachel Knapp, F. Hardtstock, Julia Krieger, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104245-104245
Closed Access | Times Cited: 11
Rachel Knapp, F. Hardtstock, Julia Krieger, et al.
Multiple Sclerosis and Related Disorders (2022) Vol. 68, pp. 104245-104245
Closed Access | Times Cited: 11
Prognostic indicators for hospitalization and ICU admission in people with multiple sclerosis and COVID-19: an analysis of the COVID-19 in MS global data sharing initiative dataset
Maria Garcia-Dominguez, Vincent Kipkorir, Bahadar S. Srichawla
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 2, pp. 720-725
Open Access | Times Cited: 1
Maria Garcia-Dominguez, Vincent Kipkorir, Bahadar S. Srichawla
Annals of Medicine and Surgery (2024) Vol. 86, Iss. 2, pp. 720-725
Open Access | Times Cited: 1
Vaccine response in people with multiple sclerosis treated with fumarates
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 3
Matthew Tremblay, Sandra Vukusic, Mathura Shanmugasundaram, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2023) Vol. 9, Iss. 3
Open Access | Times Cited: 3
Comparing the risk of serious infections in patients with and without MS: A German claims data analysis
Rachel Knapp, F. Hardtstock, Thomas Wilke, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 72, pp. 104583-104583
Closed Access | Times Cited: 1
Rachel Knapp, F. Hardtstock, Thomas Wilke, et al.
Multiple Sclerosis and Related Disorders (2023) Vol. 72, pp. 104583-104583
Closed Access | Times Cited: 1
Interplay between age and disease-modifying treatments in influencing infection risk in multiple sclerosis
Sarah Lena Susanna Jacober, Giulio Disanto, Rosaria Sacco, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 14, pp. 1765-1775
Closed Access | Times Cited: 1
Sarah Lena Susanna Jacober, Giulio Disanto, Rosaria Sacco, et al.
Multiple Sclerosis Journal (2023) Vol. 29, Iss. 14, pp. 1765-1775
Closed Access | Times Cited: 1
Coronavirus disease 2019 infection among working-aged people with multiple sclerosis and the impact of disease-modifying therapies
Chantelle Murley, Emma Pettersson, Jan Hillert, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2024) Vol. 10, Iss. 2
Open Access
Chantelle Murley, Emma Pettersson, Jan Hillert, et al.
Multiple Sclerosis Journal - Experimental Translational and Clinical (2024) Vol. 10, Iss. 2
Open Access
Cytokine profile in multiple sclerosis patients with and without Covid-19
Tetiana Halenova, Nataliia H. Raksha, Tetiana B. Vovk, et al.
Wiadomości Lekarskie (2024) Vol. 77, Iss. 4, pp. 640-645
Closed Access
Tetiana Halenova, Nataliia H. Raksha, Tetiana B. Vovk, et al.
Wiadomości Lekarskie (2024) Vol. 77, Iss. 4, pp. 640-645
Closed Access
SARS-CoV-2 Vaccination Responses in Anti-CD20-Treated Progressive Multiple Sclerosis Patients Show Immunosenescence in Antigen-Specific B and T Cells
Sara De Biasi, Alin Liviu Ciobanu, Elena Santacroce, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 924-924
Open Access
Sara De Biasi, Alin Liviu Ciobanu, Elena Santacroce, et al.
Vaccines (2024) Vol. 12, Iss. 8, pp. 924-924
Open Access
Biogenic silver nanoparticles synthesized using rose petals: Potential to inhibit multidrug-resistant bacterial pathogens in disabled patients
Salam S. Alsharari, Fadaa Alown, Fuád Ameén, et al.
South African Journal of Botany (2024) Vol. 174, pp. 405-409
Closed Access
Salam S. Alsharari, Fadaa Alown, Fuád Ameén, et al.
South African Journal of Botany (2024) Vol. 174, pp. 405-409
Closed Access
Real-World Safety and Effectiveness of Dimethyl Fumarate in Patients with MS: Results from the ESTEEM Phase 4 and PROCLAIM Phase 3 Studies with a Focus on Older Patients
Yang Mao‐Draayer, Amit Bar‐Or, Konstantin Balashov, et al.
Advances in Therapy (2024)
Open Access
Yang Mao‐Draayer, Amit Bar‐Or, Konstantin Balashov, et al.
Advances in Therapy (2024)
Open Access
Approaches to vaccine prevention in multiple sclerosis
D. S. Kasatkin, D. S. Korobko, M. D. Matson, et al.
S S Korsakov Journal of Neurology and Psychiatry (2022) Vol. 122, Iss. 9, pp. 29-29
Closed Access | Times Cited: 1
D. S. Kasatkin, D. S. Korobko, M. D. Matson, et al.
S S Korsakov Journal of Neurology and Psychiatry (2022) Vol. 122, Iss. 9, pp. 29-29
Closed Access | Times Cited: 1
COVID-19 Symptoms and Immunotherapy in People with Multiple Sclerosis: An Analysis of the COVID-19 in MS Global Data Sharing Initiative Dataset
Maria Garcia-Dominguez, Bahadar S. Srichawla, Vincent Kipkorir
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
Maria Garcia-Dominguez, Bahadar S. Srichawla, Vincent Kipkorir
medRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access
BLOOD BIOCHEMICAL PARAMETERS IN PATIENTS WITH MULTIPLE SCLEROSIS WHO HAD SARS-COV-2 INFECTION
Tetiana Halenova, Maryna Kalashnikova, Vitaliy Karbovskiy, et al.
Bulletin of Taras Shevchenko National University of Kyiv Series Biology (2023) Vol. 95, Iss. 4, pp. 13-19
Open Access
Tetiana Halenova, Maryna Kalashnikova, Vitaliy Karbovskiy, et al.
Bulletin of Taras Shevchenko National University of Kyiv Series Biology (2023) Vol. 95, Iss. 4, pp. 13-19
Open Access
